nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—migraine	0.38	1	CbGaD
Thalidomide—CYP1A1—Propranolol—migraine	0.0414	0.106	CbGbCtD
Thalidomide—PTGS1—Valproic Acid—migraine	0.0326	0.0839	CbGbCtD
Thalidomide—CYP2E1—Amitriptyline—migraine	0.0276	0.0711	CbGbCtD
Thalidomide—CYP3A5—Propranolol—migraine	0.0248	0.0639	CbGbCtD
Thalidomide—CYP2C19—Timolol—migraine	0.0225	0.0578	CbGbCtD
Thalidomide—CYP3A5—Amitriptyline—migraine	0.0215	0.0552	CbGbCtD
Thalidomide—CYP2C19—Propranolol—migraine	0.02	0.0515	CbGbCtD
Thalidomide—CYP3A5—Valproic Acid—migraine	0.0196	0.0503	CbGbCtD
Thalidomide—CYP1A2—Propranolol—migraine	0.0185	0.0475	CbGbCtD
Thalidomide—CYP2C19—Amitriptyline—migraine	0.0173	0.0446	CbGbCtD
Thalidomide—CYP3A5—Verapamil—migraine	0.017	0.0438	CbGbCtD
Thalidomide—CYP1A2—Amitriptyline—migraine	0.016	0.0411	CbGbCtD
Thalidomide—CYP2C19—Valproic Acid—migraine	0.0158	0.0406	CbGbCtD
Thalidomide—CYP1A2—Valproic Acid—migraine	0.0146	0.0375	CbGbCtD
Thalidomide—CYP2C9—Amitriptyline—migraine	0.0144	0.037	CbGbCtD
Thalidomide—CYP2C19—Topiramate—migraine	0.0142	0.0366	CbGbCtD
Thalidomide—CYP2C19—Verapamil—migraine	0.0138	0.0354	CbGbCtD
Thalidomide—CYP2C9—Valproic Acid—migraine	0.0131	0.0338	CbGbCtD
Thalidomide—CYP1A2—Verapamil—migraine	0.0127	0.0326	CbGbCtD
Thalidomide—CYP2C9—Verapamil—migraine	0.0114	0.0294	CbGbCtD
Thalidomide—FGFR2—skull—migraine	0.00385	0.174	CbGeAlD
Thalidomide—Pomalidomide—TNF—migraine	0.00212	0.632	CrCbGaD
Thalidomide—NFKB1—trigeminal ganglion—migraine	0.00131	0.0593	CbGeAlD
Thalidomide—Menadione—MTHFR—migraine	0.00123	0.368	CrCbGaD
Thalidomide—TNF—Type II diabetes mellitus—CACNA1A—migraine	0.00123	0.0369	CbGpPWpGaD
Thalidomide—FGFR2—neck—migraine	0.00114	0.0516	CbGeAlD
Thalidomide—CRBN—trigeminal ganglion—migraine	0.0011	0.0497	CbGeAlD
Thalidomide—NFKB1—cardiovascular system—migraine	0.000946	0.0428	CbGeAlD
Thalidomide—NFKB1—amb2 Integrin signaling—LRP1—migraine	0.00094	0.0282	CbGpPWpGaD
Thalidomide—FGFR2—brainstem—migraine	0.00087	0.0394	CbGeAlD
Thalidomide—TNF—amb2 Integrin signaling—LRP1—migraine	0.000716	0.0215	CbGpPWpGaD
Thalidomide—FGFR2—cardiovascular system—migraine	0.00071	0.0321	CbGeAlD
Thalidomide—TNF—Cellular roles of Anthrax toxin—PGR—migraine	0.000678	0.0203	CbGpPWpGaD
Thalidomide—NFKB1—head—migraine	0.00064	0.029	CbGeAlD
Thalidomide—NFKB1—nervous system—migraine	0.000607	0.0275	CbGeAlD
Thalidomide—NFKB1—Apoptosis—LTA—migraine	0.000595	0.0178	CbGpPWpGaD
Thalidomide—NFKB1—central nervous system—migraine	0.000585	0.0265	CbGeAlD
Thalidomide—NFKB1—cerebellum—migraine	0.000571	0.0259	CbGeAlD
Thalidomide—NFKB1—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—FOS—migraine	0.000552	0.0166	CbGpPWpGaD
Thalidomide—CRBN—head—migraine	0.000537	0.0243	CbGeAlD
Thalidomide—NFKB1—B Cell Receptor Signaling Pathway—MEF2D—migraine	0.00053	0.0159	CbGpPWpGaD
Thalidomide—CRBN—nervous system—migraine	0.000509	0.023	CbGeAlD
Thalidomide—PTGS1—blood vessel—migraine	0.000506	0.0229	CbGeAlD
Thalidomide—TNF—Monoamine Transport—SLC6A4—migraine	0.000493	0.0148	CbGpPWpGaD
Thalidomide—CRBN—central nervous system—migraine	0.00049	0.0222	CbGeAlD
Thalidomide—CYP2E1—Folate-Alcohol and Cancer Pathway—MTHFR—migraine	0.000485	0.0145	CbGpPWpGaD
Thalidomide—PTGS2—blood vessel—migraine	0.000484	0.0219	CbGeAlD
Thalidomide—FGFR2—head—migraine	0.000481	0.0218	CbGeAlD
Thalidomide—CRBN—cerebellum—migraine	0.000479	0.0217	CbGeAlD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—ATP1A3—migraine	0.000466	0.014	CbGpPWpGaD
Thalidomide—NFKB1—brain—migraine	0.000464	0.021	CbGeAlD
Thalidomide—NFKB1—Estrogen signaling pathway—ESR1—migraine	0.000459	0.0137	CbGpPWpGaD
Thalidomide—FGFR2—nervous system—migraine	0.000456	0.0206	CbGeAlD
Thalidomide—TNF—Apoptosis—LTA—migraine	0.000453	0.0136	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—RAMP1—migraine	0.000447	0.0134	CbGpPWpGaD
Thalidomide—FGFR2—central nervous system—migraine	0.000439	0.0199	CbGeAlD
Thalidomide—NFKB1—Notch Signaling Pathway—NOTCH4—migraine	0.00043	0.0129	CbGpPWpGaD
Thalidomide—FGFR2—cerebellum—migraine	0.000429	0.0194	CbGeAlD
Thalidomide—NFKB1—Estrogen signaling pathway—FOS—migraine	0.000413	0.0124	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—HTR3A—migraine	0.000397	0.0119	CbGpPWpGaD
Thalidomide—PTGS1—Prostaglandin Synthesis and Regulation—EDNRA—migraine	0.000393	0.0118	CbGpPWpGaD
Thalidomide—CRBN—brain—migraine	0.000389	0.0176	CbGeAlD
Thalidomide—NFKB1—Notch Signaling Pathway—NOTCH3—migraine	0.000366	0.011	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—ATP1A3—migraine	0.000355	0.0106	CbGpPWpGaD
Thalidomide—FGFR2—brain—migraine	0.000349	0.0158	CbGeAlD
Thalidomide—TNF—Alzheimers Disease—LRP1—migraine	0.000347	0.0104	CbGpPWpGaD
Thalidomide—NFKB1—Oxidative Stress—FOS—migraine	0.000334	0.01	CbGpPWpGaD
Thalidomide—NFKB1—Osteopontin-mediated events—FOS—migraine	0.000325	0.00975	CbGpPWpGaD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—TGFBR2—migraine	0.000321	0.00962	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—MEF2D—migraine	0.00032	0.00958	CbGpPWpGaD
Thalidomide—PTGS2—Prostaglandin Synthesis and Regulation—EDNRA—migraine	0.000312	0.00935	CbGpPWpGaD
Thalidomide—CYP1A1—Estrogen Receptor Pathway—ESR1—migraine	0.000303	0.00907	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—HTR3A—migraine	0.000302	0.00905	CbGpPWpGaD
Thalidomide—PTGS2—trigeminal ganglion—migraine	0.000299	0.0135	CbGeAlD
Thalidomide—NFKB1—Neural Crest Differentiation—NOTCH4—migraine	0.000287	0.00861	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—MTHFR—migraine	0.000273	0.00818	CbGpPWpGaD
Thalidomide—FGFR2—Neural Crest Differentiation—NOTCH4—migraine	0.000273	0.00817	CbGpPWpGaD
Thalidomide—NFKB1—Aryl Hydrocarbon Receptor—ESR1—migraine	0.000263	0.00789	CbGpPWpGaD
Thalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—FOS—migraine	0.00026	0.0078	CbGpPWpGaD
Thalidomide—CYP2C9—cardiovascular system—migraine	0.000247	0.0112	CbGeAlD
Thalidomide—TNF—TGF-beta Receptor Signaling—TGFBR2—migraine	0.000245	0.00733	CbGpPWpGaD
Thalidomide—NFKB1—Neural Crest Differentiation—NOTCH3—migraine	0.000244	0.00732	CbGpPWpGaD
Thalidomide—CYP2E1—cardiovascular system—migraine	0.000234	0.0106	CbGeAlD
Thalidomide—NFKB1—Structural Pathway of Interleukin 1 (IL-1)—FOS—migraine	0.000233	0.00699	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Metabolism and Selenoproteins—FOS—migraine	0.000233	0.00699	CbGpPWpGaD
Thalidomide—FGFR2—Neural Crest Differentiation—NOTCH3—migraine	0.000232	0.00695	CbGpPWpGaD
Thalidomide—PTGS1—cardiovascular system—migraine	0.000226	0.0102	CbGeAlD
Thalidomide—NFKB1—Canonical NF-kappaB pathway—TNF—migraine	0.000222	0.00666	CbGpPWpGaD
Thalidomide—NFKB1—EBV LMP1 signaling—TNF—migraine	0.000222	0.00666	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—MTHFR—migraine	0.000222	0.00665	CbGpPWpGaD
Thalidomide—PTGS2—cardiovascular system—migraine	0.000216	0.00977	CbGeAlD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—FOS—migraine	0.000209	0.00626	CbGpPWpGaD
Thalidomide—NFKB1—IL-4 Signaling Pathway—FOS—migraine	0.000209	0.00626	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—MTHFR—migraine	0.000208	0.00623	CbGpPWpGaD
Thalidomide—NFKB1—RANKL/RANK Signaling Pathway—FOS—migraine	0.000206	0.00617	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor—ESR1—migraine	0.000201	0.00601	CbGpPWpGaD
Thalidomide—FGFR2—FGF signaling pathway—FOS—migraine	0.000198	0.00594	CbGpPWpGaD
Thalidomide—CYP1A2—Estrogen Receptor Pathway—ESR1—migraine	0.000193	0.00578	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of Telomerase—ESR1—migraine	0.000193	0.00577	CbGpPWpGaD
Thalidomide—NFKB1—IL12-mediated signaling events—FOS—migraine	0.000192	0.00575	CbGpPWpGaD
Thalidomide—NFKB1—Fc-epsilon receptor I signaling in mast cells—FOS—migraine	0.000189	0.00568	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—HTR1A—migraine	0.000189	0.00565	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—TAC1—migraine	0.000186	0.00556	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—SCN1A—migraine	0.000185	0.00556	CbGpPWpGaD
Thalidomide—NFKB1—LPA receptor mediated events—FOS—migraine	0.000182	0.00546	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—SLC6A4—migraine	0.000182	0.00546	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—FOS—migraine	0.00018	0.00539	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—PGR—migraine	0.00018	0.00539	CbGpPWpGaD
Thalidomide—NFKB1—Leptin signaling pathway—ESR1—migraine	0.000178	0.00534	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—MTHFR—migraine	0.000176	0.00528	CbGpPWpGaD
Thalidomide—NFKB1—BCR signaling pathway—FOS—migraine	0.000176	0.00527	CbGpPWpGaD
Thalidomide—CYP1A1—head—migraine	0.000174	0.00788	CbGeAlD
Thalidomide—NFKB1—Regulation of Telomerase—FOS—migraine	0.000174	0.0052	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—CALCA—migraine	0.000171	0.00514	CbGpPWpGaD
Thalidomide—NFKB1—amb2 Integrin signaling—TNF—migraine	0.000171	0.00511	CbGpPWpGaD
Thalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOS—migraine	0.000169	0.00507	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—MTHFR—migraine	0.000169	0.00507	CbGpPWpGaD
Thalidomide—NFKB1—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—migraine	0.000166	0.00499	CbGpPWpGaD
Thalidomide—CYP1A1—nervous system—migraine	0.000165	0.00747	CbGeAlD
Thalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—FOS—migraine	0.000162	0.00485	CbGpPWpGaD
Thalidomide—NFKB1—TRAF6 Mediated Induction of proinflammatory cytokines—FOS—migraine	0.000161	0.00481	CbGpPWpGaD
Thalidomide—TNF—TGF-beta Receptor Signaling—FOS—migraine	0.000159	0.00477	CbGpPWpGaD
Thalidomide—CYP1A1—central nervous system—migraine	0.000159	0.00719	CbGeAlD
Thalidomide—CYP2E1—head—migraine	0.000159	0.00718	CbGeAlD
Thalidomide—NFKB1—Developmental Biology—SCN2A—migraine	0.000158	0.00473	CbGpPWpGaD
Thalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—migraine	0.000154	0.00463	CbGpPWpGaD
Thalidomide—PTGS1—Overview of nanoparticle effects—TNF—migraine	0.000154	0.0046	CbGpPWpGaD
Thalidomide—PTGS1—head—migraine	0.000153	0.00692	CbGeAlD
Thalidomide—NFKB1—IL23-mediated signaling events—TNF—migraine	0.000152	0.00455	CbGpPWpGaD
Thalidomide—CYP2E1—nervous system—migraine	0.00015	0.00681	CbGeAlD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—FOS—migraine	0.000149	0.00448	CbGpPWpGaD
Thalidomide—PTGS2—head—migraine	0.000146	0.00662	CbGeAlD
Thalidomide—NFKB1—MyD88 cascade initiated on plasma membrane—FOS—migraine	0.000145	0.00435	CbGpPWpGaD
Thalidomide—PTGS1—nervous system—migraine	0.000145	0.00656	CbGeAlD
Thalidomide—CYP2E1—central nervous system—migraine	0.000145	0.00656	CbGeAlD
Thalidomide—NFKB1—Developmental Biology—MEF2D—migraine	0.000144	0.00432	CbGpPWpGaD
Thalidomide—NFKB1—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—FOS—migraine	0.000144	0.00431	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—HTR1A—migraine	0.000144	0.0043	CbGpPWpGaD
Thalidomide—CYP2E1—cerebellum—migraine	0.000142	0.00641	CbGeAlD
Thalidomide—TNF—SIDS Susceptibility Pathways—TAC1—migraine	0.000141	0.00424	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—SCN1A—migraine	0.000141	0.00423	CbGpPWpGaD
Thalidomide—NFKB1—MyD88 dependent cascade initiated on endosome—FOS—migraine	0.000141	0.00423	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—TGFBR2—migraine	0.000141	0.00422	CbGpPWpGaD
Thalidomide—NFKB1—BDNF signaling pathway—BDNF—migraine	0.000141	0.00422	CbGpPWpGaD
Thalidomide—CYP1A1—Oxidative Stress—FOS—migraine	0.00014	0.00419	CbGpPWpGaD
Thalidomide—PTGS1—central nervous system—migraine	0.00014	0.00632	CbGeAlD
Thalidomide—NFKB1—TCR Signaling Pathway—FOS—migraine	0.000139	0.00416	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—SLC6A4—migraine	0.000139	0.00416	CbGpPWpGaD
Thalidomide—PTGS2—nervous system—migraine	0.000139	0.00627	CbGeAlD
Thalidomide—NFKB1—Apoptosis Modulation and Signaling—FOS—migraine	0.000138	0.00412	CbGpPWpGaD
Thalidomide—NFKB1—TWEAK Signaling Pathway—TNF—migraine	0.000137	0.00411	CbGpPWpGaD
Thalidomide—NFKB1—Corticotropin-releasing hormone—FOS—migraine	0.000136	0.00409	CbGpPWpGaD
Thalidomide—NFKB1—Toll Like Receptor 9 (TLR9) Cascade—FOS—migraine	0.000136	0.00409	CbGpPWpGaD
Thalidomide—TNF—Downstream signaling in naïve CD8+ T cells—FOS—migraine	0.000135	0.00406	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—MTHFR—migraine	0.000134	0.00403	CbGpPWpGaD
Thalidomide—NFKB1—MyD88:Mal cascade initiated on plasma membrane—FOS—migraine	0.000134	0.00402	CbGpPWpGaD
Thalidomide—PTGS2—central nervous system—migraine	0.000133	0.00604	CbGeAlD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—BDNF—migraine	0.000132	0.00396	CbGpPWpGaD
Thalidomide—PTGS2—cerebellum—migraine	0.00013	0.0059	CbGeAlD
Thalidomide—NFKB1—MAPK Signaling Pathway—TGFBR2—migraine	0.000129	0.00388	CbGpPWpGaD
Thalidomide—NFKB1—MyD88-independent cascade—FOS—migraine	0.000129	0.00385	CbGpPWpGaD
Thalidomide—NFKB1—TNF receptor signaling pathway —TNF—migraine	0.000128	0.00382	CbGpPWpGaD
Thalidomide—NFKB1—Aryl Hydrocarbon Receptor—TNF—migraine	0.000128	0.00382	CbGpPWpGaD
Thalidomide—CYP1A1—brain—migraine	0.000126	0.00571	CbGeAlD
Thalidomide—TNF—Spinal Cord Injury—BDNF—migraine	0.000126	0.00377	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—FOS—migraine	0.000126	0.00376	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—BDNF—migraine	0.000125	0.00373	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—ESR1—migraine	0.000124	0.00372	CbGpPWpGaD
Thalidomide—NFKB1—Ceramide signaling pathway—TNF—migraine	0.000123	0.0037	CbGpPWpGaD
Thalidomide—NFKB1—Senescence-Associated Secretory Phenotype (SASP)—FOS—migraine	0.000123	0.00368	CbGpPWpGaD
Thalidomide—PTGS2—Overview of nanoparticle effects—TNF—migraine	0.000122	0.00366	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—SCN2A—migraine	0.00012	0.0036	CbGpPWpGaD
Thalidomide—NFKB1—Angiopoietin receptor Tie2-mediated signaling—TNF—migraine	0.000119	0.00358	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—TNF—migraine	0.000117	0.00352	CbGpPWpGaD
Thalidomide—NFKB1—Activated TLR4 signalling—FOS—migraine	0.000116	0.00347	CbGpPWpGaD
Thalidomide—CYP2E1—brain—migraine	0.000115	0.00521	CbGeAlD
Thalidomide—NFKB1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—migraine	0.000114	0.00341	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—BDNF—migraine	0.000112	0.00337	CbGpPWpGaD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—TNF—migraine	0.000112	0.00336	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—HTR2A—migraine	0.000112	0.00335	CbGpPWpGaD
Thalidomide—PTGS1—brain—migraine	0.000111	0.00502	CbGeAlD
Thalidomide—NFKB1—Cardiac Hypertrophic Response—TNF—migraine	0.000111	0.00331	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—ESR1—migraine	0.00011	0.0033	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MEF2D—migraine	0.00011	0.00329	CbGpPWpGaD
Thalidomide—NFKB1—Toll Like Receptor 4 (TLR4) Cascade—FOS—migraine	0.000109	0.00326	CbGpPWpGaD
Thalidomide—PTGS2—brain—migraine	0.000106	0.00479	CbGeAlD
Thalidomide—FGFR2—Cardiac Hypertrophic Response—TNF—migraine	0.000105	0.00315	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—MTHFR—migraine	0.000105	0.00314	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOS—migraine	0.000105	0.00314	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—ESR1—migraine	0.000102	0.00305	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—BDNF—migraine	0.000101	0.00302	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TGFBR2—migraine	9.86e-05	0.00296	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—FOS—migraine	9.8e-05	0.00294	CbGpPWpGaD
Thalidomide—NFKB1—Toll-Like Receptors Cascades—FOS—migraine	9.69e-05	0.0029	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—ESR1—migraine	9.6e-05	0.00288	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—FOS—migraine	9.56e-05	0.00287	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—TNF—migraine	9.56e-05	0.00286	CbGpPWpGaD
Thalidomide—NFKB1—BDNF signaling pathway—FOS—migraine	9.53e-05	0.00285	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—BDNF—migraine	9.49e-05	0.00284	CbGpPWpGaD
Thalidomide—NFKB1—Signaling events mediated by HDAC Class I—TNF—migraine	9.12e-05	0.00273	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—FOS—migraine	8.98e-05	0.00269	CbGpPWpGaD
Thalidomide—Agranulocytosis—Topiramate—migraine	8.83e-05	0.000512	CcSEcCtD
Thalidomide—Dry mouth—Valproic Acid—migraine	8.82e-05	0.000512	CcSEcCtD
Thalidomide—Malnutrition—Gabapentin—migraine	8.78e-05	0.00051	CcSEcCtD
Thalidomide—Dizziness—Propranolol—migraine	8.77e-05	0.000509	CcSEcCtD
Thalidomide—Asthenia—Verapamil—migraine	8.75e-05	0.000508	CcSEcCtD
Thalidomide—Confusional state—Valproic Acid—migraine	8.72e-05	0.000506	CcSEcCtD
Thalidomide—Flatulence—Gabapentin—migraine	8.66e-05	0.000502	CcSEcCtD
Thalidomide—Oedema—Valproic Acid—migraine	8.65e-05	0.000502	CcSEcCtD
Thalidomide—Bradycardia—Topiramate—migraine	8.64e-05	0.000502	CcSEcCtD
Thalidomide—Pruritus—Verapamil—migraine	8.63e-05	0.000501	CcSEcCtD
Thalidomide—Tension—Gabapentin—migraine	8.62e-05	0.0005	CcSEcCtD
Thalidomide—Angioedema—Timolol—migraine	8.62e-05	0.0005	CcSEcCtD
Thalidomide—Dysgeusia—Gabapentin—migraine	8.6e-05	0.000499	CcSEcCtD
Thalidomide—Infection—Valproic Acid—migraine	8.59e-05	0.000499	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—BDNF—migraine	8.57e-05	0.00257	CbGpPWpGaD
Thalidomide—Nervousness—Gabapentin—migraine	8.53e-05	0.000495	CcSEcCtD
Thalidomide—Rhinitis—Topiramate—migraine	8.51e-05	0.000494	CcSEcCtD
Thalidomide—TNF—Spinal Cord Injury—FOS—migraine	8.51e-05	0.00255	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—HTR2A—migraine	8.51e-05	0.00255	CbGpPWpGaD
Thalidomide—Back pain—Gabapentin—migraine	8.5e-05	0.000493	CcSEcCtD
Thalidomide—Hepatitis—Topiramate—migraine	8.49e-05	0.000493	CcSEcCtD
Thalidomide—Nervous system disorder—Valproic Acid—migraine	8.48e-05	0.000492	CcSEcCtD
Thalidomide—Vertigo—Timolol—migraine	8.48e-05	0.000492	CcSEcCtD
Thalidomide—Thrombocytopenia—Valproic Acid—migraine	8.47e-05	0.000491	CcSEcCtD
Thalidomide—Syncope—Timolol—migraine	8.46e-05	0.000491	CcSEcCtD
Thalidomide—NFKB1—Transcriptional regulation of white adipocyte differentiation—TNF—migraine	8.45e-05	0.00253	CbGpPWpGaD
Thalidomide—Hypoaesthesia—Topiramate—migraine	8.45e-05	0.00049	CcSEcCtD
Thalidomide—Muscle spasms—Gabapentin—migraine	8.45e-05	0.00049	CcSEcCtD
Thalidomide—Tachycardia—Valproic Acid—migraine	8.44e-05	0.00049	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—ESR1—migraine	8.43e-05	0.00253	CbGpPWpGaD
Thalidomide—Vomiting—Propranolol—migraine	8.43e-05	0.000489	CcSEcCtD
Thalidomide—Pharyngitis—Topiramate—migraine	8.43e-05	0.000489	CcSEcCtD
Thalidomide—NFKB1—MAPK Signaling Pathway—FOS—migraine	8.42e-05	0.00252	CbGpPWpGaD
Thalidomide—Skin disorder—Valproic Acid—migraine	8.4e-05	0.000487	CcSEcCtD
Thalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—migraine	8.39e-05	0.00251	CbGpPWpGaD
Thalidomide—Urinary tract disorder—Topiramate—migraine	8.38e-05	0.000487	CcSEcCtD
Thalidomide—Oedema peripheral—Topiramate—migraine	8.36e-05	0.000485	CcSEcCtD
Thalidomide—Hyperhidrosis—Valproic Acid—migraine	8.36e-05	0.000485	CcSEcCtD
Thalidomide—Rash—Propranolol—migraine	8.36e-05	0.000485	CcSEcCtD
Thalidomide—Dermatitis—Propranolol—migraine	8.35e-05	0.000485	CcSEcCtD
Thalidomide—Diarrhoea—Verapamil—migraine	8.35e-05	0.000484	CcSEcCtD
Thalidomide—Palpitations—Timolol—migraine	8.34e-05	0.000484	CcSEcCtD
Thalidomide—Urethral disorder—Topiramate—migraine	8.32e-05	0.000483	CcSEcCtD
Thalidomide—PTGS2—Selenium Micronutrient Network—MTHFR—migraine	8.31e-05	0.00249	CbGpPWpGaD
Thalidomide—Loss of consciousness—Timolol—migraine	8.29e-05	0.000481	CcSEcCtD
Thalidomide—Vision blurred—Gabapentin—migraine	8.28e-05	0.00048	CcSEcCtD
Thalidomide—Anorexia—Valproic Acid—migraine	8.24e-05	0.000478	CcSEcCtD
Thalidomide—Cough—Timolol—migraine	8.23e-05	0.000478	CcSEcCtD
Thalidomide—Tremor—Gabapentin—migraine	8.23e-05	0.000478	CcSEcCtD
Thalidomide—Visual impairment—Topiramate—migraine	8.18e-05	0.000475	CcSEcCtD
Thalidomide—Ill-defined disorder—Gabapentin—migraine	8.15e-05	0.000473	CcSEcCtD
Thalidomide—Hypertension—Timolol—migraine	8.14e-05	0.000473	CcSEcCtD
Thalidomide—Anaemia—Gabapentin—migraine	8.12e-05	0.000471	CcSEcCtD
Thalidomide—Hypotension—Valproic Acid—migraine	8.08e-05	0.000469	CcSEcCtD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—FOS—migraine	8.08e-05	0.00242	CbGpPWpGaD
Thalidomide—Agitation—Gabapentin—migraine	8.07e-05	0.000468	CcSEcCtD
Thalidomide—Dizziness—Verapamil—migraine	8.07e-05	0.000468	CcSEcCtD
Thalidomide—Arthralgia—Timolol—migraine	8.03e-05	0.000466	CcSEcCtD
Thalidomide—Chest pain—Timolol—migraine	8.03e-05	0.000466	CcSEcCtD
Thalidomide—Myalgia—Timolol—migraine	8.03e-05	0.000466	CcSEcCtD
Thalidomide—Erythema multiforme—Topiramate—migraine	8.03e-05	0.000466	CcSEcCtD
Thalidomide—Angioedema—Gabapentin—migraine	8.03e-05	0.000466	CcSEcCtD
Thalidomide—Anxiety—Timolol—migraine	8e-05	0.000464	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Timolol—migraine	7.98e-05	0.000463	CcSEcCtD
Thalidomide—Discomfort—Timolol—migraine	7.94e-05	0.00046	CcSEcCtD
Thalidomide—Eye disorder—Topiramate—migraine	7.93e-05	0.00046	CcSEcCtD
Thalidomide—Malaise—Gabapentin—migraine	7.92e-05	0.00046	CcSEcCtD
Thalidomide—Tinnitus—Topiramate—migraine	7.92e-05	0.000459	CcSEcCtD
Thalidomide—Vertigo—Gabapentin—migraine	7.89e-05	0.000458	CcSEcCtD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—TNF—migraine	7.88e-05	0.00236	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—TNF—migraine	7.88e-05	0.00236	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Valproic Acid—migraine	7.88e-05	0.000457	CcSEcCtD
Thalidomide—Cardiac disorder—Topiramate—migraine	7.88e-05	0.000457	CcSEcCtD
Thalidomide—Syncope—Gabapentin—migraine	7.88e-05	0.000457	CcSEcCtD
Thalidomide—Nausea—Propranolol—migraine	7.88e-05	0.000457	CcSEcCtD
Thalidomide—Leukopenia—Gabapentin—migraine	7.86e-05	0.000456	CcSEcCtD
Thalidomide—Dry mouth—Timolol—migraine	7.85e-05	0.000456	CcSEcCtD
Thalidomide—Insomnia—Valproic Acid—migraine	7.82e-05	0.000454	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—BDNF—migraine	7.79e-05	0.00233	CbGpPWpGaD
Thalidomide—Paraesthesia—Valproic Acid—migraine	7.77e-05	0.000451	CcSEcCtD
Thalidomide—Palpitations—Gabapentin—migraine	7.76e-05	0.000451	CcSEcCtD
Thalidomide—Confusional state—Timolol—migraine	7.76e-05	0.00045	CcSEcCtD
Thalidomide—NFKB1—Cellular Senescence—FOS—migraine	7.76e-05	0.00233	CbGpPWpGaD
Thalidomide—Vomiting—Verapamil—migraine	7.76e-05	0.00045	CcSEcCtD
Thalidomide—Loss of consciousness—Gabapentin—migraine	7.72e-05	0.000448	CcSEcCtD
Thalidomide—Dyspnoea—Valproic Acid—migraine	7.71e-05	0.000447	CcSEcCtD
Thalidomide—Angiopathy—Topiramate—migraine	7.7e-05	0.000447	CcSEcCtD
Thalidomide—Oedema—Timolol—migraine	7.7e-05	0.000447	CcSEcCtD
Thalidomide—Rash—Verapamil—migraine	7.69e-05	0.000446	CcSEcCtD
Thalidomide—Somnolence—Valproic Acid—migraine	7.69e-05	0.000446	CcSEcCtD
Thalidomide—Dermatitis—Verapamil—migraine	7.68e-05	0.000446	CcSEcCtD
Thalidomide—Immune system disorder—Topiramate—migraine	7.67e-05	0.000445	CcSEcCtD
Thalidomide—Cough—Gabapentin—migraine	7.67e-05	0.000445	CcSEcCtD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—FOS—migraine	7.66e-05	0.0023	CbGpPWpGaD
Thalidomide—Mediastinal disorder—Topiramate—migraine	7.65e-05	0.000444	CcSEcCtD
Thalidomide—Infection—Timolol—migraine	7.65e-05	0.000444	CcSEcCtD
Thalidomide—Headache—Verapamil—migraine	7.64e-05	0.000443	CcSEcCtD
Thalidomide—Chills—Topiramate—migraine	7.62e-05	0.000442	CcSEcCtD
Thalidomide—Dyspepsia—Valproic Acid—migraine	7.61e-05	0.000442	CcSEcCtD
Thalidomide—Convulsion—Gabapentin—migraine	7.61e-05	0.000442	CcSEcCtD
Thalidomide—NFKB1—Selenium Micronutrient Network—TNF—migraine	7.59e-05	0.00228	CbGpPWpGaD
Thalidomide—Hypertension—Gabapentin—migraine	7.58e-05	0.00044	CcSEcCtD
Thalidomide—Shock—Timolol—migraine	7.57e-05	0.00044	CcSEcCtD
Thalidomide—Nervous system disorder—Timolol—migraine	7.55e-05	0.000438	CcSEcCtD
Thalidomide—Decreased appetite—Valproic Acid—migraine	7.52e-05	0.000436	CcSEcCtD
Thalidomide—Alopecia—Topiramate—migraine	7.5e-05	0.000435	CcSEcCtD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—TNF—migraine	7.48e-05	0.00224	CbGpPWpGaD
Thalidomide—Myalgia—Gabapentin—migraine	7.48e-05	0.000434	CcSEcCtD
Thalidomide—Chest pain—Gabapentin—migraine	7.48e-05	0.000434	CcSEcCtD
Thalidomide—Arthralgia—Gabapentin—migraine	7.48e-05	0.000434	CcSEcCtD
Thalidomide—Skin disorder—Timolol—migraine	7.48e-05	0.000434	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Valproic Acid—migraine	7.47e-05	0.000433	CcSEcCtD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—FOS—migraine	7.47e-05	0.00224	CbGpPWpGaD
Thalidomide—Fatigue—Valproic Acid—migraine	7.46e-05	0.000433	CcSEcCtD
Thalidomide—Anxiety—Gabapentin—migraine	7.45e-05	0.000433	CcSEcCtD
Thalidomide—Hyperhidrosis—Timolol—migraine	7.44e-05	0.000432	CcSEcCtD
Thalidomide—Mental disorder—Topiramate—migraine	7.44e-05	0.000432	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—migraine	7.43e-05	0.000431	CcSEcCtD
Thalidomide—Pain—Valproic Acid—migraine	7.4e-05	0.000429	CcSEcCtD
Thalidomide—Constipation—Valproic Acid—migraine	7.4e-05	0.000429	CcSEcCtD
Thalidomide—Malnutrition—Topiramate—migraine	7.39e-05	0.000429	CcSEcCtD
Thalidomide—Discomfort—Gabapentin—migraine	7.39e-05	0.000429	CcSEcCtD
Thalidomide—Anorexia—Timolol—migraine	7.34e-05	0.000426	CcSEcCtD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—TNF—migraine	7.33e-05	0.0022	CbGpPWpGaD
Thalidomide—Dry mouth—Gabapentin—migraine	7.31e-05	0.000424	CcSEcCtD
Thalidomide—Flatulence—Topiramate—migraine	7.28e-05	0.000423	CcSEcCtD
Thalidomide—Tension—Topiramate—migraine	7.25e-05	0.000421	CcSEcCtD
Thalidomide—Nausea—Verapamil—migraine	7.25e-05	0.00042	CcSEcCtD
Thalidomide—Dysgeusia—Topiramate—migraine	7.24e-05	0.00042	CcSEcCtD
Thalidomide—Confusional state—Gabapentin—migraine	7.23e-05	0.00042	CcSEcCtD
Thalidomide—Hypotension—Timolol—migraine	7.19e-05	0.000417	CcSEcCtD
Thalidomide—Nervousness—Topiramate—migraine	7.18e-05	0.000417	CcSEcCtD
Thalidomide—Oedema—Gabapentin—migraine	7.17e-05	0.000416	CcSEcCtD
Thalidomide—Back pain—Topiramate—migraine	7.15e-05	0.000415	CcSEcCtD
Thalidomide—Feeling abnormal—Valproic Acid—migraine	7.13e-05	0.000414	CcSEcCtD
Thalidomide—Infection—Gabapentin—migraine	7.12e-05	0.000413	CcSEcCtD
Thalidomide—Muscle spasms—Topiramate—migraine	7.11e-05	0.000412	CcSEcCtD
Thalidomide—Gastrointestinal pain—Valproic Acid—migraine	7.07e-05	0.00041	CcSEcCtD
Thalidomide—Shock—Gabapentin—migraine	7.05e-05	0.000409	CcSEcCtD
Thalidomide—Nervous system disorder—Gabapentin—migraine	7.03e-05	0.000408	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—migraine	7.02e-05	0.0021	CbGpPWpGaD
Thalidomide—Thrombocytopenia—Gabapentin—migraine	7.02e-05	0.000407	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Timolol—migraine	7.01e-05	0.000407	CcSEcCtD
Thalidomide—Tachycardia—Gabapentin—migraine	7e-05	0.000406	CcSEcCtD
Thalidomide—Vision blurred—Topiramate—migraine	6.97e-05	0.000404	CcSEcCtD
Thalidomide—Skin disorder—Gabapentin—migraine	6.96e-05	0.000404	CcSEcCtD
Thalidomide—Insomnia—Timolol—migraine	6.96e-05	0.000404	CcSEcCtD
Thalidomide—Hyperhidrosis—Gabapentin—migraine	6.93e-05	0.000402	CcSEcCtD
Thalidomide—Tremor—Topiramate—migraine	6.92e-05	0.000402	CcSEcCtD
Thalidomide—Paraesthesia—Timolol—migraine	6.91e-05	0.000401	CcSEcCtD
Thalidomide—Urticaria—Valproic Acid—migraine	6.87e-05	0.000399	CcSEcCtD
Thalidomide—Dyspnoea—Timolol—migraine	6.86e-05	0.000398	CcSEcCtD
Thalidomide—Ill-defined disorder—Topiramate—migraine	6.86e-05	0.000398	CcSEcCtD
Thalidomide—Somnolence—Timolol—migraine	6.84e-05	0.000397	CcSEcCtD
Thalidomide—Abdominal pain—Valproic Acid—migraine	6.84e-05	0.000397	CcSEcCtD
Thalidomide—Body temperature increased—Valproic Acid—migraine	6.84e-05	0.000397	CcSEcCtD
Thalidomide—Anorexia—Gabapentin—migraine	6.83e-05	0.000397	CcSEcCtD
Thalidomide—Anaemia—Topiramate—migraine	6.83e-05	0.000396	CcSEcCtD
Thalidomide—Agitation—Topiramate—migraine	6.79e-05	0.000394	CcSEcCtD
Thalidomide—Dyspepsia—Timolol—migraine	6.78e-05	0.000393	CcSEcCtD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—TNF—migraine	6.75e-05	0.00202	CbGpPWpGaD
Thalidomide—Hypotension—Gabapentin—migraine	6.7e-05	0.000389	CcSEcCtD
Thalidomide—Decreased appetite—Timolol—migraine	6.69e-05	0.000388	CcSEcCtD
Thalidomide—Malaise—Topiramate—migraine	6.66e-05	0.000387	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Timolol—migraine	6.65e-05	0.000386	CcSEcCtD
Thalidomide—Vertigo—Topiramate—migraine	6.64e-05	0.000385	CcSEcCtD
Thalidomide—Fatigue—Timolol—migraine	6.64e-05	0.000385	CcSEcCtD
Thalidomide—Syncope—Topiramate—migraine	6.63e-05	0.000385	CcSEcCtD
Thalidomide—Leukopenia—Topiramate—migraine	6.62e-05	0.000384	CcSEcCtD
Thalidomide—Pain—Timolol—migraine	6.58e-05	0.000382	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Gabapentin—migraine	6.53e-05	0.000379	CcSEcCtD
Thalidomide—Palpitations—Topiramate—migraine	6.53e-05	0.000379	CcSEcCtD
Thalidomide—Loss of consciousness—Topiramate—migraine	6.5e-05	0.000377	CcSEcCtD
Thalidomide—Insomnia—Gabapentin—migraine	6.48e-05	0.000376	CcSEcCtD
Thalidomide—Cough—Topiramate—migraine	6.45e-05	0.000374	CcSEcCtD
Thalidomide—Paraesthesia—Gabapentin—migraine	6.44e-05	0.000374	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—ESR1—migraine	6.42e-05	0.00193	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—FOS—migraine	6.42e-05	0.00192	CbGpPWpGaD
Thalidomide—Convulsion—Topiramate—migraine	6.4e-05	0.000372	CcSEcCtD
Thalidomide—Dyspnoea—Gabapentin—migraine	6.39e-05	0.000371	CcSEcCtD
Thalidomide—Hypertension—Topiramate—migraine	6.38e-05	0.00037	CcSEcCtD
Thalidomide—Somnolence—Gabapentin—migraine	6.37e-05	0.00037	CcSEcCtD
Thalidomide—Hypersensitivity—Valproic Acid—migraine	6.37e-05	0.00037	CcSEcCtD
Thalidomide—Feeling abnormal—Timolol—migraine	6.34e-05	0.000368	CcSEcCtD
Thalidomide—Dyspepsia—Gabapentin—migraine	6.31e-05	0.000366	CcSEcCtD
Thalidomide—Gastrointestinal pain—Timolol—migraine	6.3e-05	0.000365	CcSEcCtD
Thalidomide—Arthralgia—Topiramate—migraine	6.29e-05	0.000365	CcSEcCtD
Thalidomide—Chest pain—Topiramate—migraine	6.29e-05	0.000365	CcSEcCtD
Thalidomide—Myalgia—Topiramate—migraine	6.29e-05	0.000365	CcSEcCtD
Thalidomide—Anxiety—Topiramate—migraine	6.27e-05	0.000364	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Topiramate—migraine	6.25e-05	0.000363	CcSEcCtD
Thalidomide—Decreased appetite—Gabapentin—migraine	6.23e-05	0.000362	CcSEcCtD
Thalidomide—Discomfort—Topiramate—migraine	6.22e-05	0.000361	CcSEcCtD
Thalidomide—Asthenia—Valproic Acid—migraine	6.21e-05	0.00036	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Gabapentin—migraine	6.19e-05	0.000359	CcSEcCtD
Thalidomide—Fatigue—Gabapentin—migraine	6.18e-05	0.000359	CcSEcCtD
Thalidomide—Dry mouth—Topiramate—migraine	6.15e-05	0.000357	CcSEcCtD
Thalidomide—Pain—Gabapentin—migraine	6.13e-05	0.000356	CcSEcCtD
Thalidomide—Constipation—Gabapentin—migraine	6.13e-05	0.000356	CcSEcCtD
Thalidomide—Pruritus—Valproic Acid—migraine	6.12e-05	0.000355	CcSEcCtD
Thalidomide—Urticaria—Timolol—migraine	6.12e-05	0.000355	CcSEcCtD
Thalidomide—Body temperature increased—Timolol—migraine	6.09e-05	0.000353	CcSEcCtD
Thalidomide—Abdominal pain—Timolol—migraine	6.09e-05	0.000353	CcSEcCtD
Thalidomide—Confusional state—Topiramate—migraine	6.08e-05	0.000353	CcSEcCtD
Thalidomide—Oedema—Topiramate—migraine	6.03e-05	0.00035	CcSEcCtD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—migraine	6.01e-05	0.0018	CbGpPWpGaD
Thalidomide—Infection—Topiramate—migraine	5.99e-05	0.000348	CcSEcCtD
Thalidomide—Shock—Topiramate—migraine	5.93e-05	0.000344	CcSEcCtD
Thalidomide—Diarrhoea—Valproic Acid—migraine	5.92e-05	0.000343	CcSEcCtD
Thalidomide—Nervous system disorder—Topiramate—migraine	5.92e-05	0.000343	CcSEcCtD
Thalidomide—Feeling abnormal—Gabapentin—migraine	5.91e-05	0.000343	CcSEcCtD
Thalidomide—Thrombocytopenia—Topiramate—migraine	5.91e-05	0.000343	CcSEcCtD
Thalidomide—Tachycardia—Topiramate—migraine	5.89e-05	0.000342	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—CALCRL—migraine	5.88e-05	0.00176	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RAMP1—migraine	5.88e-05	0.00176	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—FOS—migraine	5.87e-05	0.00176	CbGpPWpGaD
Thalidomide—Gastrointestinal pain—Gabapentin—migraine	5.86e-05	0.00034	CcSEcCtD
Thalidomide—Skin disorder—Topiramate—migraine	5.86e-05	0.00034	CcSEcCtD
Thalidomide—Hyperhidrosis—Topiramate—migraine	5.83e-05	0.000338	CcSEcCtD
Thalidomide—Anorexia—Topiramate—migraine	5.75e-05	0.000334	CcSEcCtD
Thalidomide—Dizziness—Valproic Acid—migraine	5.72e-05	0.000332	CcSEcCtD
Thalidomide—Urticaria—Gabapentin—migraine	5.7e-05	0.000331	CcSEcCtD
Thalidomide—Hypersensitivity—Timolol—migraine	5.67e-05	0.000329	CcSEcCtD
Thalidomide—Body temperature increased—Gabapentin—migraine	5.67e-05	0.000329	CcSEcCtD
Thalidomide—Abdominal pain—Gabapentin—migraine	5.67e-05	0.000329	CcSEcCtD
Thalidomide—Hypotension—Topiramate—migraine	5.64e-05	0.000327	CcSEcCtD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—migraine	5.62e-05	0.00169	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RAMP1—migraine	5.58e-05	0.00167	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CALCRL—migraine	5.58e-05	0.00167	CbGpPWpGaD
Thalidomide—Asthenia—Timolol—migraine	5.52e-05	0.000321	CcSEcCtD
Thalidomide—Vomiting—Valproic Acid—migraine	5.5e-05	0.000319	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Topiramate—migraine	5.5e-05	0.000319	CcSEcCtD
Thalidomide—Insomnia—Topiramate—migraine	5.46e-05	0.000317	CcSEcCtD
Thalidomide—Rash—Valproic Acid—migraine	5.45e-05	0.000316	CcSEcCtD
Thalidomide—Dermatitis—Valproic Acid—migraine	5.45e-05	0.000316	CcSEcCtD
Thalidomide—Pruritus—Timolol—migraine	5.45e-05	0.000316	CcSEcCtD
Thalidomide—Headache—Valproic Acid—migraine	5.42e-05	0.000314	CcSEcCtD
Thalidomide—Paraesthesia—Topiramate—migraine	5.42e-05	0.000314	CcSEcCtD
Thalidomide—Dyspnoea—Topiramate—migraine	5.38e-05	0.000312	CcSEcCtD
Thalidomide—Somnolence—Topiramate—migraine	5.36e-05	0.000311	CcSEcCtD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—migraine	5.34e-05	0.0016	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—TNF—migraine	5.34e-05	0.0016	CbGpPWpGaD
Thalidomide—Dyspepsia—Topiramate—migraine	5.31e-05	0.000308	CcSEcCtD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—migraine	5.3e-05	0.00159	CbGpPWpGaD
Thalidomide—Hypersensitivity—Gabapentin—migraine	5.28e-05	0.000307	CcSEcCtD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—TNF—migraine	5.27e-05	0.00158	CbGpPWpGaD
Thalidomide—Diarrhoea—Timolol—migraine	5.27e-05	0.000306	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—FOS—migraine	5.26e-05	0.00158	CbGpPWpGaD
Thalidomide—Decreased appetite—Topiramate—migraine	5.24e-05	0.000304	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Topiramate—migraine	5.21e-05	0.000302	CcSEcCtD
Thalidomide—Fatigue—Topiramate—migraine	5.2e-05	0.000302	CcSEcCtD
Thalidomide—Pain—Topiramate—migraine	5.16e-05	0.000299	CcSEcCtD
Thalidomide—Constipation—Topiramate—migraine	5.16e-05	0.000299	CcSEcCtD
Thalidomide—Asthenia—Gabapentin—migraine	5.14e-05	0.000299	CcSEcCtD
Thalidomide—Nausea—Valproic Acid—migraine	5.14e-05	0.000298	CcSEcCtD
Thalidomide—Dizziness—Timolol—migraine	5.09e-05	0.000295	CcSEcCtD
Thalidomide—Pruritus—Gabapentin—migraine	5.07e-05	0.000294	CcSEcCtD
Thalidomide—Feeling abnormal—Topiramate—migraine	4.97e-05	0.000288	CcSEcCtD
Thalidomide—Gastrointestinal pain—Topiramate—migraine	4.93e-05	0.000286	CcSEcCtD
Thalidomide—Diarrhoea—Gabapentin—migraine	4.91e-05	0.000285	CcSEcCtD
Thalidomide—Vomiting—Timolol—migraine	4.9e-05	0.000284	CcSEcCtD
Thalidomide—Rash—Timolol—migraine	4.85e-05	0.000282	CcSEcCtD
Thalidomide—Dermatitis—Timolol—migraine	4.85e-05	0.000281	CcSEcCtD
Thalidomide—Headache—Timolol—migraine	4.82e-05	0.00028	CcSEcCtD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—TNF—migraine	4.8e-05	0.00144	CbGpPWpGaD
Thalidomide—Urticaria—Topiramate—migraine	4.79e-05	0.000278	CcSEcCtD
Thalidomide—Abdominal pain—Topiramate—migraine	4.77e-05	0.000277	CcSEcCtD
Thalidomide—Body temperature increased—Topiramate—migraine	4.77e-05	0.000277	CcSEcCtD
Thalidomide—FGFR2—Disease—LRP1—migraine	4.74e-05	0.00142	CbGpPWpGaD
Thalidomide—Dizziness—Gabapentin—migraine	4.74e-05	0.000275	CcSEcCtD
Thalidomide—Nausea—Timolol—migraine	4.57e-05	0.000265	CcSEcCtD
Thalidomide—Vomiting—Gabapentin—migraine	4.56e-05	0.000265	CcSEcCtD
Thalidomide—NFKB1—MAPK Signaling Pathway—TNF—migraine	4.53e-05	0.00136	CbGpPWpGaD
Thalidomide—Rash—Gabapentin—migraine	4.52e-05	0.000262	CcSEcCtD
Thalidomide—Dermatitis—Gabapentin—migraine	4.52e-05	0.000262	CcSEcCtD
Thalidomide—PTGS1—Selenium Micronutrient Network—TNF—migraine	4.51e-05	0.00135	CbGpPWpGaD
Thalidomide—Headache—Gabapentin—migraine	4.49e-05	0.000261	CcSEcCtD
Thalidomide—Hypersensitivity—Topiramate—migraine	4.44e-05	0.000258	CcSEcCtD
Thalidomide—Asthenia—Topiramate—migraine	4.33e-05	0.000251	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—HTR1D—migraine	4.28e-05	0.00128	CbGpPWpGaD
Thalidomide—Pruritus—Topiramate—migraine	4.27e-05	0.000248	CcSEcCtD
Thalidomide—Nausea—Gabapentin—migraine	4.26e-05	0.000247	CcSEcCtD
Thalidomide—Diarrhoea—Topiramate—migraine	4.13e-05	0.000239	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TNF—migraine	4.09e-05	0.00122	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR1D—migraine	4.06e-05	0.00122	CbGpPWpGaD
Thalidomide—Dizziness—Topiramate—migraine	3.99e-05	0.000231	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—HTR2B—migraine	3.97e-05	0.00119	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—migraine	3.97e-05	0.00119	CbGpPWpGaD
Thalidomide—Vomiting—Topiramate—migraine	3.84e-05	0.000223	CcSEcCtD
Thalidomide—Rash—Topiramate—migraine	3.8e-05	0.000221	CcSEcCtD
Thalidomide—Dermatitis—Topiramate—migraine	3.8e-05	0.000221	CcSEcCtD
Thalidomide—Headache—Topiramate—migraine	3.78e-05	0.000219	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—HTR2B—migraine	3.77e-05	0.00113	CbGpPWpGaD
Thalidomide—Nausea—Topiramate—migraine	3.58e-05	0.000208	CcSEcCtD
Thalidomide—PTGS2—Selenium Micronutrient Network—TNF—migraine	3.58e-05	0.00107	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LRP1—migraine	3.5e-05	0.00105	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—migraine	3.4e-05	0.00102	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—migraine	3.4e-05	0.00102	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LRP1—migraine	3.32e-05	0.000995	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CACNA1A—migraine	3.17e-05	0.000949	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—FOS—migraine	3.14e-05	0.00094	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CALCA—migraine	3.06e-05	0.000916	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—FOS—migraine	2.98e-05	0.000892	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—migraine	2.83e-05	0.000848	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOTCH4—migraine	2.69e-05	0.000805	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR1B—migraine	2.59e-05	0.000776	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOTCH4—migraine	2.55e-05	0.000763	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CACNA1A—migraine	2.51e-05	0.000753	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR1A—migraine	2.49e-05	0.000747	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFBR2—migraine	2.46e-05	0.000738	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR1B—migraine	2.46e-05	0.000737	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PGR—migraine	2.46e-05	0.000736	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NPS—migraine	2.46e-05	0.000736	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TAC1—migraine	2.46e-05	0.000736	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR2C—migraine	2.41e-05	0.000722	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR1A—migraine	2.37e-05	0.000709	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CACNA1A—migraine	2.37e-05	0.000709	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CACNA1A—migraine	2.36e-05	0.000708	CbGpPWpGaD
Thalidomide—PTGS2—Disease—LRP1—migraine	2.35e-05	0.000706	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EDNRA—migraine	2.34e-05	0.000702	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NPS—migraine	2.33e-05	0.000698	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PGR—migraine	2.33e-05	0.000698	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TAC1—migraine	2.33e-05	0.000698	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR2C—migraine	2.29e-05	0.000685	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOTCH3—migraine	2.28e-05	0.000684	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CALCA—migraine	2.26e-05	0.000676	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CACNA1A—migraine	2.23e-05	0.000668	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EDNRA—migraine	2.22e-05	0.000666	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOTCH3—migraine	2.17e-05	0.000649	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CALCA—migraine	2.14e-05	0.000641	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR7—migraine	2.11e-05	0.000632	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR7—migraine	2e-05	0.0006	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MTHFR—migraine	2e-05	0.000599	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—migraine	1.93e-05	0.000577	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—migraine	1.91e-05	0.000572	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FOS—migraine	1.83e-05	0.000548	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CACNA1A—migraine	1.83e-05	0.000547	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFBR2—migraine	1.82e-05	0.000544	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FOS—migraine	1.73e-05	0.00052	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFBR2—migraine	1.72e-05	0.000517	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CACNA1A—migraine	1.66e-05	0.000499	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CALCA—migraine	1.52e-05	0.000455	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR2A—migraine	1.48e-05	0.000443	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CACNA1A—migraine	1.42e-05	0.000426	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR2A—migraine	1.4e-05	0.00042	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ESR1—migraine	1.31e-05	0.000393	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ESR1—migraine	1.24e-05	0.000373	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFBR2—migraine	1.22e-05	0.000366	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MTHFR—migraine	1.05e-05	0.000314	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTHFR—migraine	9.93e-06	0.000297	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—migraine	8.31e-06	0.000249	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—migraine	7.83e-06	0.000235	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—migraine	7.81e-06	0.000234	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—migraine	7.38e-06	0.000221	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—migraine	6.04e-06	0.000181	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—migraine	5.51e-06	0.000165	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—migraine	4.7e-06	0.000141	CbGpPWpGaD
